

Special Issue

New Horizons in Rare Rheumatic Diseases: Towards Precision Medicine

Message from the Guest Editor

Rare rheumatic diseases pose growing challenges in both clinical practice and research, but they also offer unique opportunities to advance precision medicine. In this future perspective, new serological and genetic biomarkers might discover new insights, and the possible use of artificial intelligence might offer great horizons to ameliorate diagnostic and therapeutic criteria and protocols, ultimately enhancing care for patients with rare rheumatic diseases. We warmly invite outstanding experts to contribute to this Special Issue on future challenges and advances in rare rheumatic diseases research. Submissions may include original articles, reviews, systematic reviews, and other types on topics including, but not limited to, the following:

- Novel diagnostic biomarkers and genetic insights
- Artificial intelligence applications in rare disease diagnosis and management
- Multidisciplinary approaches to complex clinical presentations
- Clinical trial designs and therapeutic innovations in rare rheumatic diseases


Guest Editor

Prof. Dr. Francesca Bandinelli

Rheumatology Division, Santa Maria Nuova Hospital, Multidimensional Department, Usl Tuscany Center, Piazza Santa Maria Nuova 1, 50122 Florence, Italy

Deadline for manuscript submissions

28 February 2027



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 7.2
Indexed in PubMed




mdpi.com/si/277111

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 7.2
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the first half of 2026).